<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Oncology</title><link>https://nrouizem.github.io/test/oncology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/oncology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Sat, 15 Mar 2025 01:16:48 +0000</lastBuildDate><item><title>From Graz to global — Innophore’s journey with NVIDIA’s BioNeMo</title><link>https://www.drugdiscoverytrends.com/from-graz-to-global-innophores-journey-with-nvidias-bionemo/</link><description>Austrian biotech startup Innophore is leveraging NVIDIA’s computational power to enhance its AI-driven drug safety screening and binding-site analysis through its Catalophore platform. The company gained significant exposure when highlighted by NVIDIA CEO Jensen Huang, leading to increasing interest and opportunities for collaboration.</description><pubDate>Tue, 28 Jan 2025 19:56:15 +0000</pubDate></item><item><title>How an engineered algae-based biologic aims to break the annual $5B cycle of c. diff reinfection</title><link>https://www.drugdiscoverytrends.com/how-an-engineered-algae-based-biologic-aims-to-break-the-annual-5b-cycle-of-c-diff-reinfection/</link><description>Researchers are developing an engineered algae-based biologic to combat Clostridioides difficile, a superbug responsible for 29,000 U.S. deaths each year due to severe gastrointestinal issues. This innovation aims to disrupt the annual $5 billion cycle of C. diff reinfection by offering a new treatment avenue for patients at risk of recurring infections.</description><pubDate>Thu, 30 Jan 2025 05:06:20 +0000</pubDate></item><item><title>Lilly’s FDA approval for Omvoh close up: Nearly 90% of one-year responders maintained remission through two years</title><link>https://www.drugdiscoverytrends.com/lillys-fda-approval-for-omvoh-close-up-nearly-90-of-one-year-responders-maintained-remission-through-two-years/</link><description>The FDA has approved Omvoh (mirikizumab-mrkz) for Crohn's disease, marking its second inflammatory bowel disease (IBD) authorization since 2023 and the first biologic launch in over 15 years with Phase 3 two-year efficacy data. In the pivotal VIVID-1 trial, 53% of patients treated with Omvoh achieved clinical remission at one year, significantly outperforming the 36% remission rate in the placebo group.</description><pubDate>Fri, 31 Jan 2025 19:00:44 +0000</pubDate></item><item><title>How 3T Biosciences’ platform targets immunologically cold solid tumors</title><link>https://www.drugdiscoverytrends.com/3t-biosciences-targeted-strategy-for-mss-colorectal-cancer/</link><description>3T Biosciences is tackling the challenge of immunotherapy resistance in solid tumors, particularly focusing on microsatellite stable colorectal cancer (MSS CRC), where over 90% of cases do not respond to checkpoint inhibitors. Their innovative platform aims to improve treatment outcomes for various cancer types that exhibit resistance to current immunotherapy approaches.</description><pubDate>Sat, 01 Feb 2025 05:12:51 +0000</pubDate></item><item><title>How Capsida’s unconventional funding strategy and capsid technology promise to reshape CNS treatments</title><link>https://www.drugdiscoverytrends.com/how-capsidas-unconventional-funding-strategy-and-capsid-technology-promise-to-reshape-cns-treatments/</link><description>Capsida Biotherapeutics is set to receive a $40 million license payment from AbbVie, who will exercise its option on their neurodegenerative disease program. The startup has successfully grown its funding through collaborations with major pharmaceutical companies, leveraging its innovative capsid technology to reshape Central Nervous System treatments.</description><pubDate>Sat, 01 Feb 2025 21:05:12 +0000</pubDate></item><item><title>The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root</title><link>https://www.drugdiscoverytrends.com/the-fda-fast-tracked-gnsc-001-gene-therapy-targets-osteoarthritis-at-its-root/</link><description>The FDA has fast-tracked the GNSC-001 gene therapy, which aims to address the root causes of osteoarthritis, a debilitating condition affecting over 30 million Americans and resulting in significant healthcare costs. This innovative treatment represents a crucial step toward meeting the urgent medical need for effective osteoarthritis therapies.</description><pubDate>Tue, 04 Feb 2025 19:16:27 +0000</pubDate></item><item><title>ONI’s Aplo Scope achieves 20 nm imaging resolution, aims to cut drug target validation time</title><link>https://www.drugdiscoverytrends.com/onis-aplo-scope-achieves-20-nm-imaging-resolution-aims-to-cut-drug-target-validation-time/</link><description>Oxford Nanoimaging (ONI) has unveiled the Aplo Scope super-resolution microscope, offering imaging precision down to 20 nm and designed to simplify the analysis of molecular interactions at the nanoscale. This innovative, compact microscope aims to accelerate drug target validation processes for researchers.</description><pubDate>Tue, 11 Feb 2025 01:12:34 +0000</pubDate></item><item><title>Flatiron Health sees shift from “what if” to “what is” in real-world evidence in oncology</title><link>https://www.drugdiscoverytrends.com/flatiron-health-sees-shift-from-what-if-to-what-is-in-real-world-evidence-in-oncology/</link><description>Flatiron Health is transforming the future of oncology by shifting the conversation from theoretical possibilities of AI in healthcare to practical applications that are currently underway. According to head of outcomes research Blythe Adamson, the recent developments in AI, particularly post-ChatGPT, have alleviated skepticism and are now driving real-world evidence in cancer care.</description><pubDate>Wed, 12 Feb 2025 03:39:41 +0000</pubDate></item><item><title>Rosnilimab phase 2b trial shows promise in treating RA</title><link>https://www.drugdiscoverytrends.com/rosnilimab-phase-2b-trial-shows-promise-in-treating-ra/</link><description>Results from the phase 2b trial of rosnilimab show promise in treating rheumatoid arthritis (RA) by targeting the PD-1 pathway, potentially resetting the immune system for improved patient outcomes. Current treatments often fail to provide long-term remission, necessitating ongoing adjustments among existing therapies.</description><pubDate>Wed, 19 Feb 2025 14:07:47 +0000</pubDate></item><item><title>Solutions for CAR-Engineered Cell Characterization</title><link>https://www.fiercebiotech.com/resource/solutions-car-engineered-cell-characterization</link><description>Cell Signaling Technology (CST) has unveiled purpose-built tools, including recombinant antibodies targeting scFv linkers like G4S and Whitlow/218, to accelerate CAR-engineered cell characterization and development. The solutions aim to bypass the costly, time-intensive process of anti-idiotype antibody creation while streamlining workflows for researchers.</description><pubDate>Wed, 26 Feb 2025 14:49:25 +0000</pubDate></item><item><title>COTA Healthcare announces AI milestone in real-world oncology data</title><link>https://www.drugdiscoverytrends.com/cota-healthcare-announces-ai-milestone-in-real-world-oncology-data/</link><description>COTA Healthcare has introduced a groundbreaking generative AI platform that revolutionizes the large-scale curation of real-world oncology data, enhancing both accuracy and profitability. This significant advancement marks a notable departure from previous industry efforts to automate the traditionally labor-intensive process of RWD abstraction.</description><pubDate>Wed, 26 Feb 2025 19:00:13 +0000</pubDate></item><item><title>3 Ways to Ensure Your Marketing Fills Your Life Science BD Pipeline</title><link>https://www.fiercebiotech.com/resource/3-ways-ensure-your-marketing-fills-your-life-science-bd-pipeline</link><description>The article outlines three key strategies—targeting the right Audience, effective Storytelling, and tracking Performance—to help life science companies bolster their business development pipelines through a robust marketing plan. Sponsored by Scorr Marketing, it promotes a downloadable e-book offering actionable insights to align marketing efforts with BD goals, emphasizing tools and tactics to generate qualified leads.</description><pubDate>Tue, 04 Mar 2025 06:44:11 +0000</pubDate></item><item><title>Finding Patients, Closing Treatment Gaps, and Building Better Messaging through AI and Real-World Data</title><link>https://www.fiercebiotech.com/premium/webinar/1368842</link><description>OM1's upcoming webinar, featuring experts Joseph Zabinski and Kathryn Starzyk, explores how AI-driven digital phenotyping and real-world data can help pharmaceutical teams identify underserved patient populations and align therapies with unmet clinical needs. The session will demonstrate strategies to bridge treatment gaps, refine market messaging, and ensure therapies reach overlooked communities through advanced analytics.</description><pubDate>Thu, 06 Mar 2025 20:09:20 +0000</pubDate></item><item><title>J&amp;J Axes Late-Stage Depression Trial After Underwhelming Efficacy</title><link>https://www.biospace.com/drug-development/j-j-axes-late-stage-depression-trial-after-underwhelming-efficacy</link><description>Despite aticaprant's Phase III setback, analysts say J&amp;J's neuroscience strategy remains intact, bolstered by its recent $14.6 billion acquisition of Intra-Cellular Therapeutics. The company’s confidence is further reinforced by the continued success of Spravato, its treatment for resistant depression, positioning it to maintain momentum in the sector.</description><pubDate>Fri, 07 Mar 2025 13:46:12 +0000</pubDate></item><item><title>AstraZeneca Builds Stomach Cancer Case for Imfinzi With Strong Phase III Data</title><link>https://www.biospace.com/drug-development/astrazeneca-builds-stomach-cancer-case-for-imfinzi-with-strong-phase-iii-data</link><description>AstraZeneca's cancer drug Imfinzi is poised to drive significant growth in 2025, with regulators set to decide on its expanded use in treating stomach and bladder cancers. The blockbuster therapy generated over $4.7 billion in sales last year, cementing its role as a key revenue driver for the pharmaceutical giant.</description><pubDate>Fri, 07 Mar 2025 13:58:56 +0000</pubDate></item><item><title>At $300M Kardigan startup, former MyoKardia team unveils its first drug, and it comes from Ionis</title><link>https://endpts.com/at-300m-kardigan-startup-former-myokardia-team-unveils-its-first-drug-and-it-comes-from-ionis/</link><description>Former MyoKardia executives launched a heart health biotech startup with $300 million in funding, leveraging undisclosed partnerships to secure in-licensed clinical-stage assets for cardiac therapies. The stealth-mode company remains tight-lipped about specific deals but signals a focus on advancing innovative treatments, attracting attention for its seasoned leadership and strategic collaborations.</description><pubDate>Fri, 07 Mar 2025 16:16:52 +0000</pubDate></item><item><title>J&amp;J scraps depression testing for potential blockbuster drug</title><link>https://www.biopharmadive.com/news/johnson-depression-studies-discontinue-aticaprant-neumora/741922/</link><description>A recent decision has dealt a "big blow" to a promising class of brain therapies, including Johnson &amp; Johnson’s experimental drug aticaprant and Neumora Therapeutics’ candidate, casting uncertainty over their development. While the article highlights setbacks for these specific treatments, it does not mention any new business deals, partnerships, or acquisitions related to the companies involved.</description><pubDate>Fri, 07 Mar 2025 17:08:00 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>FDA approves Neurotech therapy for rare eye disease</title><link>https://endpts.com/fda-approves-neurotech-therapy-for-rare-eye-disease/</link><description>The FDA approved Neurotech Pharmaceuticals’ first-of-its-kind cell therapy for macular telangiectasia type 2, a rare eye disease causing progressive central vision loss, marking a major advancement for patients with no prior treatment options. The therapy, which implants cells to repair retinal damage, could transform care for the condition, though the article does not mention specific business deals or partnerships related to its development.</description><pubDate>Fri, 07 Mar 2025 19:57:13 +0000</pubDate></item><item><title>Sun Pharma to acquire Checkpoint Therapeutics and its anti-PD-L1 antibody</title><link>https://endpts.com/sun-pharma-to-acquire-checkpoint-therapeutics-and-its-anti-pd-l1-antibody/</link><description>Checkpoint Therapeutics has pivoted from seeking a partnership for its newly approved cancer drug to being acquired outright by India’s Sun Pharma in a strategic immuno-oncology expansion. The deal, valued at $4.10 per share, marks a swift exit for Checkpoint and reinforces Sun Pharma’s growing footprint in cutting-edge cancer therapies.</description><pubDate>Mon, 10 Mar 2025 12:20:53 +0000</pubDate></item><item><title>Novo Nordisk’s CagriSema shows 15.7% weight loss in second pivotal trial</title><link>https://endpts.com/novo-nordisks-cagrisema-shows-15-7-weight-loss-in-second-pivotal-trial/</link><description>Novo Nordisk announced Monday that its drug CagriSema achieved 15.7% weight loss in patients with obesity and type 2 diabetes after over a year of use, marking a potential advancement in dual-treatment therapies. The result underscores the drug’s efficacy in addressing these interconnected conditions, positioning it as a promising contender in the competitive metabolic health market.</description><pubDate>Mon, 10 Mar 2025 12:21:18 +0000</pubDate></item><item><title>J&amp;J’s Oral IL-23R Blocker Sets New Standard in Plaque Psoriasis, Beating BMS’ Sotyktu</title><link>https://www.biospace.com/drug-development/j-js-oral-il-23r-blocker-sets-new-standard-in-plaque-psoriasis-beating-bmss-sotyktu</link><description>New late-stage trial data reveals Johnson &amp; Johnson’s psoriasis drug icotrokinra outperformed Bristol Myers Squibb’s Sotyktu in clearing skin and reducing symptom severity for patients with plaque psoriasis. The findings could intensify competition in the dermatology treatment market, positioning J&amp;J’s therapy as a potential challenger in this therapeutic area.</description><pubDate>Mon, 10 Mar 2025 14:03:00 +0000</pubDate></item><item><title>BMS’ Sotyktu Notches Phase III Win in Psoriatic Arthritis</title><link>https://www.biospace.com/drug-development/bms-sotyktu-notches-phase-iii-win-in-psoriatic-arthritis</link><description>In the plaque psoriasis market, Sotyktu is locked in a competitive battle with Amgen’s Otezla while bracing for new rivalry from Alumis’ investigational TYK2 inhibitor. The intensifying competition underscores the dynamic landscape of psoriasis treatments as emerging therapies threaten to disrupt established players.</description><pubDate>Mon, 10 Mar 2025 14:07:24 +0000</pubDate></item><item><title>Novo Dips After CagriSema’s Latest Lower-Than-Expected Weight Loss Readout</title><link>https://www.biospace.com/drug-development/novo-dips-after-cagrisemas-latest-lower-than-expected-weight-loss-readout</link><description>New clinical trial results revealed CagriSema, a weight-loss drug from Novo, achieved 15.7% weight reduction in diabetic patients over 68 weeks but delivered a disappointing 22.7% in non-diabetic patients by December 2024, falling short of the company’s projected 25% efficacy. The underwhelming performance in non-diabetic trials raises questions about the drug’s competitive edge in the crowded obesity treatment market.</description><pubDate>Mon, 10 Mar 2025 14:14:35 +0000</pubDate></item><item><title>Arrowhead reveals small batch of open-label data for 'non-core' kidney drug</title><link>https://endpts.com/arrowhead-reveals-small-batch-of-open-label-data-for-non-core-kidney-drug/</link><description>Arrowhead Pharmaceuticals unveiled promising new open-label data from its ARO-C3 RNAi therapy program, showing potential to improve kidney disease outcomes by targeting complement pathways in a small study involving about a dozen patients. The early-stage results highlight the therapy's novel approach to addressing kidney disorders, though no partnerships or business deals related to the program were disclosed.</description><pubDate>Mon, 10 Mar 2025 15:07:58 +0000</pubDate></item><item><title>Mineralys shares climb on study data for blood pressure drug</title><link>https://www.biopharmadive.com/news/mineralys-lorundrostat-hypertension-study-results/742000/</link><description>New studies on Mineralys' hypertension treatment have validated the drug as a promising near-commercial product, with analysts hailing it as a "derisked, almost-commercial stage cardiometabolic asset." While no specific deals or partnerships were mentioned, the data bolsters the therapy’s market potential and positions it for future commercial opportunities.</description><pubDate>Mon, 10 Mar 2025 15:30:00 +0000</pubDate></item><item><title>Trevi Therapeutics stock soars on Phase 2a chronic cough data</title><link>https://endpts.com/trevi-therapeutics-stock-soars-on-phase-2a-chronic-cough-data/</link><description>Trevi Therapeutics' chronic cough drug demonstrated a 57% reduction in 24-hour cough frequency versus placebo in a Phase 2a trial, outperforming investor expectations and sparking a 40% surge in its stock ($TRVI) at market open. The breakthrough underscores the treatment’s potential and has ignited optimism among investors about the company’s clinical and commercial prospects.</description><pubDate>Mon, 10 Mar 2025 15:51:40 +0000</pubDate></item><item><title>J&amp;J, Protagonist outline first IBD win for potential immunological blockbuster</title><link>https://endpts.com/jj-protagonist-outline-first-ibd-win-for-potential-immunological-blockbuster/</link><description>Johnson &amp; Johnson and Protagonist Therapeutics have partnered to develop an oral IL-23 drug, aiming to create a breakthrough immunology treatment. The companies announced progress toward this goal on Monday, signaling potential advancements in bringing the blockbuster drug candidate closer to market.</description><pubDate>Mon, 10 Mar 2025 16:04:34 +0000</pubDate></item><item><title>#AAD25 roundup: Data from Amgen, Bristol Myers, J&amp;J, Alumis and more</title><link>https://endpts.com/aad25-roundup-data-from-amgen-bristol-myers-jj-alumis-and-more/</link><description>At the American Academy of Dermatology annual meeting, key players like Amgen, Bristol Myers Squibb, Alumis, and Kyowa Kirin spotlighted updates on their dermatology drug pipelines, though no mergers or acquisitions were highlighted. The event emphasized breakthroughs in treatments for conditions like psoriasis and eczema, showcasing the industry’s focus on advancing innovative therapies for skin diseases.</description><pubDate>Mon, 10 Mar 2025 16:37:26 +0000</pubDate></item><item><title>Deep Dive: Cardiovascular Disease Back in the Spotlight</title><link>https://www.biospace.com/drug-development/deep-dive-cardiovascular-disease-back-in-the-spotlight</link><description>BioSpace highlights the rapid evolution of emerging therapeutic modalities, from gene editing to cell therapies, as biotech and pharma companies race to innovate in a competitive market. The article underscores the intensifying battles for dominance in this space, with advancements poised to reshape treatment paradigms and spur significant industry growth.</description><pubDate>Mon, 10 Mar 2025 16:40:00 +0000</pubDate></item><item><title>Beam shares promising first clinical data on gene editing treatment</title><link>https://endpts.com/beam-shares-promising-first-clinical-data-on-gene-editing-treatment/</link><description>Beam Therapeutics' experimental gene-editing therapy demonstrated promising results in a small trial, reducing mutant proteins linked to lung-damaging alpha-1 antitrypsin deficiency and boosting corrected protein levels in nine participants. The early data underscores the treatment's potential as a one-time fix for the genetic disorder, though the article does not mention any business deals, partnerships, or mergers.</description><pubDate>Mon, 10 Mar 2025 16:42:30 +0000</pubDate></item><item><title>Novo’s Wegovy successor disappoints in second large trial</title><link>https://www.biopharmadive.com/news/novo-nordisk-cagrisema-study-results-diabetes-weight-loss/742008/</link><description>A recent study found that CagriSema, a weight-loss therapy for individuals with obesity and diabetes, demonstrated effectiveness in aiding weight loss but fell short of outperforming Eli Lilly’s rival drug Zepbound. While the results highlight CagriSema’s potential, they solidify Zepbound’s competitive edge in the burgeoning metabolic treatment market.</description><pubDate>Mon, 10 Mar 2025 17:17:00 +0000</pubDate></item><item><title>Beam base editing therapy gets ‘proof of concept’ in rare lung disease</title><link>https://www.biopharmadive.com/news/beam-aatd-base-editing-initial-data-results-302/742015/</link><description>Beam Therapeutics' shares dropped sharply despite promising early study results showing its gene-editing technology could address the genetic cause of alpha-1 antitrypsin deficiency. The stock decline highlights investor concerns even as the company advances its innovative treatment potential.</description><pubDate>Mon, 10 Mar 2025 17:25:00 +0000</pubDate></item><item><title>BioNTech's shares dip after posting lukewarm revenue guidance</title><link>https://endpts.com/biontechs-shares-dip-after-posting-lukewarm-revenue-guidance/</link><description>BioNTech shares fell 2% after projecting lower 2025 revenues, citing reduced COVID-19 vaccine demand and oversupply challenges despite a solid $4.2 billion revenue in 2023. The company plans to pivot toward advancing cancer treatments and cost-cutting measures while preparing for new vaccine launches to offset declining pandemic-related sales.</description><pubDate>Mon, 10 Mar 2025 19:37:01 +0000</pubDate></item><item><title>Making Just-in-Time Oncology Trials Work: Overcoming Barriers and Unlocking Potential</title><link>https://www.fiercebiotech.com/premium/webinar/1368918</link><description>Just-in-time (JIT) oncology trials aim to accelerate research and improve patient access by activating trial sites only after identifying eligible patients, requiring strong collaboration between sponsors, sites, and IRBs to streamline processes and pre-negotiate agreements. An upcoming webinar will explore strategies like data-driven prescreening, standardized protocols, and centralized oversight to overcome operational barriers and expand the use of JIT trials in delivering faster, cost-effective cancer treatments.</description><pubDate>Mon, 10 Mar 2025 19:50:06 +0000</pubDate></item><item><title>The true cost of steroid-toxicity</title><link>https://www.drugdiscoverytrends.com/the-true-cost-of-steroid-toxicity/</link><description>Glucocorticoids, or steroids, are widely used as the standard treatment for autoimmune disorders due to their effectiveness in suppressing inflammation and reducing immune system activity. However, the article highlights the hidden costs and potential long-term toxicity associated with steroid use, raising concerns about their overall safety.</description><pubDate>Tue, 11 Mar 2025 01:33:58 +0000</pubDate></item><item><title>Bristol Myers buys out cell therapy partner 2seventy bio</title><link>https://endpts.com/bristol-myers-buys-out-cell-therapy-partner-2seventy-bio/</link><description>Bristol Myers Squibb has agreed to acquire 2seventy bio, its longtime partner in developing the CAR-T cell therapy Abecma for multiple myeloma, in a $286 million all-cash deal. The acquisition strengthens Bristol Myers' foothold in cancer therapies, building on the companies' existing collaboration aimed at advancing cutting-edge immunocellular treatments.</description><pubDate>Tue, 11 Mar 2025 08:13:39 +0000</pubDate></item><item><title>Arvinas and Pfizer’s PROTAC vepdegestrant works in subset of breast cancer patients</title><link>https://endpts.com/arvinas-and-pfizers-protac-vepdegestrant-works-in-subset-of-breast-cancer-patients/</link><description>Arvinas and Pfizer's partnered experimental breast cancer drug, vepdegestrant, failed to outperform existing therapies in the Phase 3 VERITAC-2 trial, casting doubt on its competitive potential. The results highlight challenges for the collaboration’s aim to deliver a differentiated treatment in the crowded protein degrader landscape.</description><pubDate>Tue, 11 Mar 2025 11:56:49 +0000</pubDate></item><item><title>Beam’s Gene Editor Achieves ‘First Ever’ Genetic Correction in AATD</title><link>https://www.biospace.com/drug-development/beams-gene-editor-achieves-first-ever-genetic-correction-in-aatd</link><description>William Blair analysts highlighted BEAM-302 as a breakthrough therapy, praising its superior efficacy in its sector in a recent investor note. While the report emphasized the drug's potential to redefine treatment standards, it did not mention any specific business deals, partnerships, or acquisitions related to the product.</description><pubDate>Tue, 11 Mar 2025 13:52:59 +0000</pubDate></item><item><title>Pfizer, Arvinas Post Mixed Late-Stage Breast Cancer Data for Closely Watched PROTAC Drug</title><link>https://www.biospace.com/drug-development/pfizer-arvinas-post-mixed-late-stage-breast-cancer-data-for-closely-watched-protac-drug</link><description>Vepdegestrant’s mixed trial results—stalling on broad progression-free survival but showing promise in a niche patient group—sparked a 43% plunge in Arvinas’ stock, with analysts casting doubt on the drug's long-term viability. While no new deals were announced, the setback raises questions about the company’s ability to attract future partnerships or advance the drug’s commercial prospects.</description><pubDate>Tue, 11 Mar 2025 14:08:28 +0000</pubDate></item><item><title>Corrected: Merck opens billion-dollar US facility to make Gardasil</title><link>https://endpts.com/merck-opens-billion-dollar-facility-to-make-bladder-cancer-immunotherapy/</link><description>Merck has launched a new North Carolina-based manufacturing facility to produce HPV vaccines, including Gardasil and Gardasil 9, to meet rising global demand for cervical cancer prevention. The plant’s opening aligns with Merck’s strategy to expand production capacity amid increasing vaccine rollout efforts worldwide.</description><pubDate>Tue, 11 Mar 2025 14:50:06 +0000</pubDate></item><item><title>Arvinas gets positive breast cancer data, but finds differentiation a hard sell</title><link>https://www.biopharmadive.com/news/arvinas-pfizer-vepdegestrant-breast-cancer-data-veritac/742135/</link><description>Arvinas and Pfizer's partnered breast cancer drug, vepdegestrant, showed promising results in a specific patient subgroup compared to fulvestrant, though it didn't meet overall trial goals. The mixed outcomes highlight the experimental therapy's potential niche benefits while underscoring the challenges of broad efficacy in cancer treatment.</description><pubDate>Tue, 11 Mar 2025 16:45:00 +0000</pubDate></item><item><title>Viking inks CordenPharma deal to boost obesity drug supply</title><link>https://www.biopharmadive.com/news/viking-cordenpharma-obesity-drug-manufacturing-deal/742139/</link><description>A biotech firm is investing $150 million in a strategic alliance to secure expanded production capacity for a high-profile weight-loss therapy, positioning itself to meet soaring demand. The partnership underscores the company’s aggressive push to capitalize on the competitive but rapidly growing market for obesity treatments.</description><pubDate>Tue, 11 Mar 2025 17:25:00 +0000</pubDate></item><item><title>Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts</title><link>https://www.biospace.com/drug-development/gilead-gsk-viiv-move-ahead-with-long-acting-hiv-options-following-early-stage-readouts</link><description>Gilead is moving directly to Phase III trials for its once-yearly lenacapavir, while GSK and ViiV are advancing their long-acting antivirals following promising early-stage results. This strategic shift highlights the ongoing competition in the development of innovative treatments in the antiviral space.</description><pubDate>Wed, 12 Mar 2025 13:13:49 +0000</pubDate></item><item><title>Roche broadens obesity drug plans with $1.65B Zealand deal</title><link>https://www.biopharmadive.com/news/roche-zealand-license-obesity-drug-amylin-petrelinitide/742278/</link><description>A Swiss pharmaceutical company has secured a deal to access an experimental amylin-targeting treatment, which it will test alongside drugs acquired from Carmot. This collaboration aims to enhance its drug development efforts in this therapeutic area.</description><pubDate>Wed, 12 Mar 2025 16:20:00 +0000</pubDate></item><item><title>Telix’s new lead-212 generator could dispel medical isotope scalability hurdles</title><link>https://www.pharmaceutical-technology.com/news/telixs-new-lead-212-generator-could-dispel-medical-isotope-scalability-hurdles/</link><description>Lead-212-based alpha emitters show significant potential in cancer therapies but face challenges in commercial supply. Their promising application in oncology is hindered by difficulties in production and distribution.</description><pubDate>Thu, 13 Mar 2025 11:34:09 +0000</pubDate></item><item><title>Montara Therapeutics adds $20M to seed fundraise for neurology pipeline</title><link>https://endpts.com/montara-therapeutics-adds-20m-to-seed-fundraise-for-neurology-pipeline/</link><description>Montara Therapeutics has secured $20 million in expanded seed financing to progress its preclinical CNS candidates, aiming to tackle safety concerns that have historically hindered research and development. This funding will help the company advance its innovative approaches in the treatment of central nervous system disorders.</description><pubDate>Thu, 13 Mar 2025 12:00:29 +0000</pubDate></item><item><title>MeiraGTx partners with cryptic AI startup Hologen to advance Parkinson's gene therapy</title><link>https://endpts.com/meiragtx-partners-with-cryptic-ai-startup-hologen-to-advance-parkinsons-gene-therapy/</link><description>MeiraGTx is spinning out its Parkinson’s disease program into a new company in partnership with an AI startup co-founded by former Google CEO Eric Schmidt. This strategic move highlights the rising trend of integrating advanced technology into biotech to enhance treatment development.</description><pubDate>Thu, 13 Mar 2025 15:32:22 +0000</pubDate></item><item><title>Vivani treats first patient with long-lasting drug implant for weight loss</title><link>https://www.pharmaceutical-technology.com/news/vivani-treats-first-patient-with-long-lasting-drug-implant-for-weight-loss/</link><description>Vivani Medical has successfully implanted its device in the first patient, following the announcement of a strategic split-off to concentrate on weight loss and diabetes implants. This move marks a significant step in the company's commitment to advancing treatments in these health areas.</description><pubDate>Thu, 13 Mar 2025 16:00:15 +0000</pubDate></item><item><title>Gedeon Richter’s once-daily endometriosis pill approved for NHS use</title><link>https://www.pharmaceutical-technology.com/news/gedeon-richters-once-daily-endometriosis-pill-approved-for-nhs-use/</link><description>NICE estimates that around 1,000 women could benefit from Ryeqo, a once-daily medication that can be taken throughout the menopause transition. This treatment aims to provide a significant improvement in the management of menopause-related symptoms.</description><pubDate>Thu, 13 Mar 2025 19:51:54 +0000</pubDate></item><item><title>MoonLake's CEO on its looming mid-year pivotal readout in skin disease</title><link>https://endpts.com/moonlakes-ceo-on-its-looming-mid-year-pivotal-readout-in-skin-disease/</link><description>MoonLake Immunotherapeutics is anticipating a significant stock-moving clinical readout for its Phase 3 trials targeting a painful inflammatory skin condition, expected around the middle of this year. This pivotal moment could considerably impact the biotech sector and the company's market position.</description><pubDate>Fri, 14 Mar 2025 09:05:36 +0000</pubDate></item><item><title>EC approves Otsuka and Lundbeck’s Rxulti for schizophrenia</title><link>https://www.pharmaceutical-technology.com/news/ec-otsuka-lundbeck-rxulti/</link><description>The European Commission has granted approval for Otsuka Pharmaceutical and Lundbeck’s atypical oral antipsychotic, Rxulti (brexpiprazole), for the treatment of schizophrenia. This approval marks a significant advancement in options available for managing this mental health condition.</description><pubDate>Fri, 14 Mar 2025 10:42:42 +0000</pubDate></item><item><title>Sutro puts lead ADC on hold, cuts staff and changes CEO</title><link>https://pharmaphorum.com/news/sutro-puts-lead-adc-hold-cuts-staff-and-changes-ceo</link><description>Sutro has put its lead ovarian cancer drug on hold and is shifting focus to three preclinical candidates in a significant restructuring of its business. This strategic pivot marks a crucial change in the company's development priorities.</description><pubDate>Fri, 14 Mar 2025 11:00:13 +0000</pubDate></item><item><title>MeiraGTx and Hologen launch AI-backed gene therapy venture</title><link>https://www.pharmaceutical-technology.com/news/meiragtx-and-hologen-launch-ai-backed-gene-therapy-venture/</link><description>MeiraGTx is set to advance its Parkinson's gene therapy into Phase III trials, bolstered by a significant funding partnership with Hologen amounting to up to $430 million. This collaboration aims to propel the development of innovative treatment options for Parkinson's disease.</description><pubDate>Fri, 14 Mar 2025 11:27:54 +0000</pubDate></item><item><title>RFK Jr. convened roundtable around ways to reduce stem cell regulation</title><link>https://endpts.com/rfk-jr-convened-roundtable-around-ways-to-reduce-stem-cell-regulation/</link><description>HHS Secretary Robert F. Kennedy Jr. hosted a regenerative medicine roundtable focused on reducing regulatory barriers for stem cell treatments. The meeting aimed to foster advancements in regenerative medicine and facilitate easier access to innovative therapies.</description><pubDate>Fri, 14 Mar 2025 15:36:02 +0000</pubDate></item><item><title>How biosimulation and virtual trials can bust through clinical trial roadblocks</title><link>https://www.drugdiscoverytrends.com/how-biosimulation-and-virtual-trials-can-bust-through-clinical-trial-roadblocks/</link><description>Over 300 million people globally are affected by rare diseases, with about 95% lacking FDA-approved treatments due to the challenges traditional clinical trials face. However, emerging biosimulation and virtual trial methods present innovative solutions to overcome these obstacles, as highlighted by Oxana Iliach, vice-chair of a relevant organization.</description><pubDate>Fri, 14 Mar 2025 15:54:00 +0000</pubDate></item><item><title>AstraZeneca director says AI must be a “thought partner” in drug discovery</title><link>https://www.pharmaceutical-technology.com/news/astrazeneca-director-says-ai-must-be-a-thought-partner-in-drug-discovery/</link><description>AstraZeneca's senior director in oncology data science highlighted the company's innovative use of AI in drug discovery during a recent presentation. The approach aims to enhance the efficiency and effectiveness of developing new cancer treatments.</description><pubDate>Fri, 14 Mar 2025 16:29:00 +0000</pubDate></item><item><title>Federal Circuit ruling keeps Amgen's Eylea biosimilar on the market</title><link>https://endpts.com/federal-circuit-ruling-keeps-amgens-eylea-biosimilar-on-the-market/</link><description>The US Court of Appeals for the Federal Circuit ruled against Regeneron in a significant patent infringement case concerning its eye drug Eylea and Amgen's biosimilar Pavblu. This decision impacts the competitive landscape in the ophthalmology market, particularly for treatments targeting age-related macular degeneration.</description><pubDate>Fri, 14 Mar 2025 19:05:53 +0000</pubDate></item></channel></rss>